ClinicalTrials.gg

Program

BTK Inhibitor HMPL-760

Also written as “HMPL-760”, “HMPL-760 planned dose 1” and “HMPL-760 planned dose 2”.

Its studies are mostly in Lymphoma, Large B-Cell, Diffuse · Lymphoma, B-Cell · Lymphoma, B-Cell, Marginal Zone, led by HUTCHMED.

Furthest: phase 3, since Jan 28, 20265 company-led studies, 1 open or runningNext primary completion: Apr 30, 2028 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
HUTCHMED51 open or runningphase 3since Jan 28, 2026Nov 19, 2021Apr 30, 2028phase 3 · NCT07409428

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 19, 2021First study: phase 1 study in Lymphoma, B-Cell, Marginal ZoneFirst studyNCT05176691 · United States, Australia, France and more
  2. Dec 10, 2021Phase 1 study in Lymphoma, B-CellNCT05190068 · 89 enrolled · China
  3. Sep 8, 2024Phase 2 study in Lymphoma, Large B-Cell, DiffuseNCT06601504 · 61 enrolled · China
  4. Jan 28, 2026Phase 3 study in Lymphoma, Large B-Cell, DiffusePhase 3 reachedNCT07409428 · 240 planned · China
  5. Jun 8, 2026Phase 1 study in Healthy ParticipantsNCT07643272 · 24 enrolled · China

Ahead

  1. Apr 30, 2028Primary completion: phase 3 study in Lymphoma, Large B-Cell, DiffuseNCT07409428

TargetBeta

BTK →read by rule
“A third-generation, reversible inhibitor of Bruton's tyrosine kinase (BTK; Bruton agammaglobulinemia tyrosine kinase), ”NCIt, by rule

Other programs on BTK

ProgramCompanyFurthest phaseStudies
ibrutinibruleJohnson & Johnsonphase 478
acalabrutinibruleAstraZenecaphase 455
zanubrutinibruleBeOne Medicinesphase 435
pirtobrutinibruleEli Lillyphase 430
ritlecitinibrulePfizerphase 342
orelabrutinibruleInnoCare Pharmaphase 327
rilzabrutinibruleSanofiphase 323
evobrutinibruleMerck KGaA, Darmstadt, Germanyphase 320
fenebrutinibHoffmann-La Rochephase 318
nemtabrutinibMerckphase 316
rocbrutinibruleLupeng Pharmaceuticalphase 315
tirabrutinibruleGilead Sciencesphase 313

Studies

All 5 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07643272Healthy Participants · China1CompletedJul 31, 202624
NCT07409428Lymphoma, Large B-Cell, Diffuse · China3RecruitingApr 30, 2028240
NCT06601504Lymphoma, Large B-Cell, Diffuse · China2CompletedMay 23, 202661
NCT05190068Lymphoma, B-Cell · China1CompletedJan 27, 202589
NCT05176691Lymphoma, B-Cell, Marginal Zone · United States, Australia, France and more1WithdrawnNov 16, 20220

How it is read

Names in the registry

  • “HMPL-760”, 4 entries
  • “HMPL-760 planned dose 1”, 1 entry
  • “HMPL-760 planned dose 2”, 1 entry
  • “Rabeprazole and HMPL-760”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.